National Viral Hepatitis Action Plan Release
It has been just over a year since the National Viral Hepatitis Action Plan 2017-2020 (Action Plan) was released. The updated Action Plan represents a new phase in the battle against viral hepatitis and is the nation’s roadmap for addressing viral hepatitis in the United States. It reflects recent trends in viral hepatitis infections and deaths, as well as new and improved strategies for prevention, care, and treatment.
Read more »
Viral Hepatitis Updates from the HHS Office of HIV/AIDS and Infectious Disease Policy
New research from the Centers for Disease Control and Prevention (CDC) suggests that the recent steep increase in cases of acute hepatitis C virus infection is associated with increases in opioid injection. Rates of hepatitis C infections increased most steeply among young people, followed by whites, and women.
Read more »
Key Performance Indicators for WHO Prequalification
WHO PQDx is a valuable initiative that improves the quality of in vitro diagnostics for under-served populations in countries where regulatory systems are weak or non-existent. However, broader attention to some of the existing inefficiencies and longer-term risks concerning the successful implementation of this important programme is needed. Our viewpoint discusses challenges of WHO PQDx, in particular around its scope, processes, timelines and financing. It also highlights the manufacturers’ responsibilities and is informed by consolidated feedback from a large number of experts working in the in vitro diagnostics and medical devices industries, along with insightful comments from WHO. The paper was accepted for publication on 17 August 2017 and assigned to Clinical Infectious Diseases’ 6 January 2018’s issue. It is freely available at https://doi.org/10.1093/cid/cix719.
Read more »
Ending the Epidemic: New Web Resource for HIV Community Leaders
Many community leaders across the United States are calling for just that: an end to the HIV/AIDS epidemic in their cities, their counties, and their states. In many ways, this is aparadigm shift – rather than asking for unambitious, incremental progress in reducing new infections and increasing viral suppression rates, communities of activists, service providers, health departments, elected officials, people living with HIV, and other key stakeholders are doing the work to create ambitious and bold plans to improve the health outcomes of all people living with and vulnerable to the virus and to drive HIV/AIDS below epidemic levels.
Read more »
Viral Hepatitis Updates from the HHS Office of HIV/AIDS and Infectious Disease Policy
As 2017 comes to a close, we would like to personally thank all our federal and community partners that have helped to advance our national efforts in the battle against viral hepatitis.
Although much has been accomplished this year, we are still losing ground. The opioid epidemic is fueling increases in hepatitis B and C, and a growing number of infants are now at risk. More than 4 million Americans from all walks of life are already infected, but just over half of them know they have the virus, and hepatitis-related deaths are at near record levels.
Read more »
HIVMA weighs in on drug pricing
HIVMA addressed the impacts of unaffordable prescription drugs with these comments to Senate Health, Education, Labor and Pension committee members in advance of their hearing on drug pricing Tuesday.
Read more »
National HIV and STD Curriculum offer CME credits
The AETC National Coordinating Resource Center and the University of Washington have developed the National HIV Curriculum, an educational web site offering free CME and CNE credits.
Read more »
Press Release: FDA approves first two-drug regimen for certain patients with HIV
The U.S. Food and Drug Administration today approved Juluca, the first complete treatment regimen containing only two drugs to treat certain adults with human immunodeficiency virus type 1 (HIV-1) instead of three or more drugs included in standard HIV treatment. Juluca is a fixed-dose tablet containing two previously approved drugs (dolutegravir and rilpivirine) to treat adults with HIV-1 infections whose virus is currently suppressed on a stable regimen for at least six months, with no history of treatment failure and no known substitutions associated with resistance to the individual components of Juluca.
Read more »
Viral Hepatitis Updates from the HHS Office of HIV/AIDS and Infectious Disease Policy
November is a time to be thankful for many reasons and here at OHAIDP, we are thankful for all our partners and our shared accomplishments.
The interest and follow up from our Hidden Casualties: Consequences of the Opioid Epidemic on the Spread of Infectious Diseases event has been phenomenal. The opioid crisis in the United States has reached epidemic levels. Our office, along with many of our partners, are continuing to address this critical health threat. If you haven’t seen the powerful webcast, you can read the event coverage in USA Today or view the event video with transcripts.
Read more »
HIVMA: STD, PrEP Resources and More
STD Curriculum launched
The University of Washington STD Prevention Training Center has developed the National STD Curriculum website addressing the epidemiology, pathogenesis, clinical manifestations, diagnosis, management, and prevention of chlamydia, gonorrhea, HSV, HPV, PID, syphilis and vaginitis. The website is free, integrates the most recent CDC STD Treatment Guidelines, and includes self-study modules for continuing education credits with interactive board-review style questions, and reference materials.
Read more »
|
|